Find research datasets worth reusing

Figure 9 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 9 Tumor sizes of EMT-6/P after dissection at day 10 in all groups compared to each other, n = 7 except for the last two groups n = 6.

Figure 8 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 8 Folds increase in caspase-3 activity and apoptosis induction, concentrations used were: baicalin 175 µM, EGCG 125 µM, baicalin, and EGCG 140 and 100 µM respectively, vincristine 643 µg/ml and positive control treated with MEM in EMT-6/V.

Figure 3 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 3 Anti-proliferative effect of EGCG in single treatment against EMT-6/P and EMT-6/V cell lines.

Figure 23 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 23 Creatinine serum levels (mg/dl) in different treatment groups. Concentrations used baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group in EMT-6/P and EMT-6/V. Including the statistical correlations between groups.

Figure 4 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 4 The sensitivity of EMT-6/P and EMT-6/V cell lines to vincristine was measured by testing decreasing concentrations of vincristine using the anti-proliferative assay (MTT).

Figure 5 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 5 Anti-proliferation effect of EGCG and baicalin in combination treatment against EMT-6/P different doses of EGCG with a fixed dose of baicalin (114 µM).

Figure 21 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 21 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group on average creatinine measured by (mg/dl) in EMT-6/P.

Figure 2 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 2 Anti-proliferative effect of baicalin in single treatment against EMT-6/P and EMT-6/V cell lines.

Figure 12 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 12 A plot of change in average tumor size (mm³) vs. time in days of treatment in EMT-6/V cell line.

Figure 20 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 20 AST serum level (U/L) in different treatment groups. Concentrations used baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group in EMT-6/P and EMT-6/V. Including the statistical correlations between groups.

opencc-by-4.0Nov 2024View details →

Identification of lipid species signature in FOLFOXIRI-resistant colorectal cancer cells

Open the record for dataset details and reuse information.

dryad28/100

Data from: Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics

Traditional means for scoring the effects of anti-cancer drugs on the growth and survival of cell lines is based on relative cell number in drug-treated and control samples and is seriously confounded by unequal division rates arising from natural biological variation and differences in culture conditions. This problem can be overcome by computing drug sensitivity on a per-division basis. The normalized growth rate inhibition (GR) approach yields per-division metrics for drug potency (GR50) and efficacy (GRmax) that are analogous to the more familiar IC50 and Emax values. In this work, we report GR-based, proliferation-corrected, drug sensitivity metrics for ~4,700 pairs of breast cancer cell lines and perturbagens. Such data are broadly useful in understanding the molecular basis of therapeutic response and resistance. Here, we use them to investigate the relationship between different measures of drug sensitivity and conclude that drug potency and efficacy exhibit high variation that is only weakly correlated. To facilitate further use of these data, computed GR curves and metrics can be browsed interactively at http://www.GRbrowser.org/.

opencc-zeroDec 2016View details →

opencc-by-4.0May 2023View details →

BRD8 is a therapeutic vulnerability for overcoming resistance to dual ER/HER2 blockade therapy in HR+/HER2+ breast cancer

<p>.rda file for Seurat object of scRNA-seq data from BT474 breast cancer cell lines treated with DMSO, Neratinib, Fulvestrant, and a combination of Neratinib and Fulvestrant.</p>

Fig. 8 in Diterpenoids from Euphorbia royleana reverse P-glycoprotein-mediated multidrug resistance in cancer cells

Fig. 8. Effects of 15 on the expression of P-gp.

Fig. 3 in Diterpenoids from Euphorbia royleana reverse P-glycoprotein-mediated multidrug resistance in cancer cells

Fig. 3. Key NOESY correlations () of compounds 1, 2, 4, 5, 6, and 8.

Fig. 1 in Diterpenoids from Euphorbia royleana reverse P-glycoprotein-mediated multidrug resistance in cancer cells

Fig. 1. The structures of compounds 1–30 and 8a.

Fig. 4. Single-crystal X in Diterpenoids from Euphorbia royleana reverse P-glycoprotein-mediated multidrug resistance in cancer cells

Fig. 4. Single-crystal X-ray structures of 1, 6, 7, and 8a.